US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

CERo Therapeutics Holdings, Inc. - Common Stock (NQ:CERO)

0.0951 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CERo Therapeutics Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Provides Shareholder Update
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened ↗
Via Stocktwits
News headline image
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Trading on OTCQB Market
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Listing on OTC Markets
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Top movers in Thursday's after hours session ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Falls Over 1%; Alphabet Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks You'll Regret Missing In Q3 ↗
 
Via Benzinga
News headline image
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
News headline image
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >